Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 21355087)

1.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD; Cancer and Leukemia Group B.

Blood. 2011 May 19;117(20):5314-20. doi: 10.1182/blood-2010-10-314260. Epub 2011 Feb 25.

2.

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J Jr, Buccheri V, Meneghetti JC.

J Nucl Med. 2010 Sep;51(9):1337-43. doi: 10.2967/jnumed.109.073197. Epub 2010 Aug 18. Erratum in: J Nucl Med. 2010 Oct;51(10):1658.

3.

ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.

Hartridge-Lambert SK, Schöder H, Lim RC, Maragulia JC, Portlock CS.

Cancer. 2013 Mar 15;119(6):1203-9. doi: 10.1002/cncr.27873. Epub 2012 Nov 6.

4.

Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).

Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG).

Leuk Lymphoma. 2013 Jan;54(1):46-52. doi: 10.3109/10428194.2012.705000. Epub 2012 Aug 21.

PMID:
22712838
5.

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M, Cwynarski K.

AIDS. 2012 Apr 24;26(7):861-5. doi: 10.1097/QAD.0b013e32835213b1.

PMID:
22333746
6.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.

J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28.

7.

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.

Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A.

Blood. 2011 Dec 8;118(24):6292-8. doi: 10.1182/blood-2011-07-368167. Epub 2011 Sep 13.

8.

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD; Cancer Leukemia Group B.

Leuk Lymphoma. 2012 Nov;53(11):2143-50. doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28.

PMID:
22421007
9.

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A.

Ann Oncol. 2010 Jan;21(1):126-32. doi: 10.1093/annonc/mdp271. Epub 2009 Jul 16.

10.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.

J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.

11.

HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM, Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M.

J Clin Oncol. 2012 Nov 20;30(33):4111-6. doi: 10.1200/JCO.2011.41.4193. Epub 2012 Oct 8.

12.

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, Chong A, Moon JH, Kim JH, Lee SM, Kim SJ, Shin HJ.

Cancer Sci. 2013 Dec;104(12):1656-61. doi: 10.1111/cas.12282. Epub 2013 Oct 23.

PMID:
24033666
13.

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.

Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, Travaini L, Preda L, Martinelli G.

Hematol Oncol. 2013 Mar;31(1):34-40. doi: 10.1002/hon.2014. Epub 2012 Mar 30.

PMID:
22473680
14.

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.

Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.

Leuk Lymphoma. 2013 Jan;54(1):76-82. doi: 10.3109/10428194.2012.701737. Epub 2012 Jul 9.

PMID:
22680774
15.

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6.

PMID:
21894546
16.

Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).

Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M.

Int J Hematol. 2010 Dec;92(5):713-24. doi: 10.1007/s12185-010-0712-8. Epub 2010 Nov 16.

PMID:
21076995
17.

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.

Cancer. 2000 May 1;88(9):2142-8.

PMID:
10813727
18.

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.

Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.

J Clin Oncol. 2012 Nov 20;30(33):4117-23. doi: 10.1200/JCO.2012.41.8137. Epub 2012 Oct 8. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590.

19.

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, Kozak T.

Leuk Lymphoma. 2012 Jan;53(1):64-70. doi: 10.3109/10428194.2011.603444. Epub 2011 Aug 24.

PMID:
21740300
20.

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Colonna P, Jais JP, Desablens B, Harousseau JL, Brière J, Boasson M, Lemevel A, Casassus P, Le Prisé PY, Guilhot F, Ghandour C, Lejeune F, Andrieu JM.

J Clin Oncol. 1996 Jun;14(6):1928-35.

PMID:
8656262
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk